Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Macular Edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

The Macular Edema pipeline market research report provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects.

Macular Edema Pipeline Products Market Segmentation by Targets

The key targets in the Macular Edema pipeline products market are Vascular Endothelial Growth Factor A, Glucocorticoid Receptor, Placenta Growth Factor, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor B, Angiopoietin 1 Receptor, Angiopoietin 2, Prostaglandin G/H Synthase 2, Vascular Endothelial Growth Factor C, and Vascular Endothelial Growth Factor Receptor. Vascular Endothelial Growth Factor Ais the leading target in the pipeline.

Macular Edema Pipeline Products Market Analysis by Targets

For more target insights into the Macular Edema pipeline products market, download a free report sample

Macular Edema Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Macular Edema pipeline products market are Vascular Endothelial Growth Factor A Inhibitor, Glucocorticoid Receptor Agonist, Placenta Growth Factor Inhibitor, Vascular Endothelial Growth Factor B Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Angiopoietin 1 Receptor Agonist, Angiopoietin 2 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Vascular Endothelial Growth Factor C Inhibitor, and Vascular Endothelial Growth Factor Receptor Inhibitor. Among the MoA, Vascular Endothelial Growth Factor A Inhibitor is the leading one.

Macular Edema Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Macular Edema pipeline products market, download a free report sample

Macular Edema Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Macular Edema pipeline products market are intravitreal, intraocular, intravenous, ophthalmic, and parenteral. Intravitreal is the leading route of administration in the pipeline.

Macular Edema Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Macular Edema pipeline products market, download a free report sample

Macular Edema Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Macular Edema pipeline products market are monoclonal antibody, small molecule, fusion protein, and synthetic peptide.

Macular Edema Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the Macular Edema pipeline products market, download a free report sample

Macular Edema Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Macular Edema pipeline products market are F. Hoffmann-La Roche Ltd, 3SBio Inc, Aerie Pharmaceuticals Inc, AsclepiX Therapeutics Inc, Celon Pharma SA, Clearside BioMedical Inc, Clonz Biotech Pvt Ltd, Coherus BioSciences Inc, Huadong Medicine Co Ltd, and Luye Pharma Group Ltd. F. Hoffmann-La Roche Ltd is the leading company in the Macular Edema pipeline products market.

Macular Edema Pipeline Products Market Analysis by Companies

To know more about the leading players in the Macular Edema pipeline products market, download a free report sample

Macular Edema Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.